Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

Padmanee Sharma; Michael Krainer; Fred Saad; Daniel Castellano; Jens Bedke; Mariusz Kwiatkowski; Akash Patnaik; Giuseppe Procopio; Paweł Wiechno; Samith Kochuparambil; Christian Thomas; José Ángel Arranz Arija; Steven L. McCune; Steinbjørn Hansen; Gedske Daugaard; Juan Ignacio Delgado Mingorance; Craig Kukard; Sumit K. Subudhi; Sreyashi Basu; Sonali Jindal; Bilal A. Siddiqui; Ana Lako; Saurabh Gupta; Viktor Fedorov; Neha P. Amin; Arancha Campos; Yumeng Wang; Justin M. David; Russell K. Pachynski

doi:10.1038/s41467-026-72242-w

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

P Padmanee Sharma M Michael Krainer F Fred Saad (Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal) D Daniel Castellano (Hospital Universitario 12 de Octubre, Madrid) J Jens Bedke (Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany) M Mariusz Kwiatkowski A Akash Patnaik G Giuseppe Procopio P Paweł Wiechno S Samith Kochuparambil C Christian Thomas J José Ángel Arranz Arija S Steven L. McCune S Steinbjørn Hansen G Gedske Daugaard J Juan Ignacio Delgado Mingorance C Craig Kukard S Sumit K. Subudhi S Sreyashi Basu S Sonali Jindal B Bilal A. Siddiqui A Ana Lako S Saurabh Gupta V Viktor Fedorov N Neha P. Amin A Arancha Campos Y Yumeng Wang (Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences) J Justin M. David R Russell K. Pachynski

Download PDF View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Nature Communications

Volume / Issue Vol. 17, Issue 1

Published May 08, 2026

DOI 10.1038/s41467-026-72242-w

ISSN 2041-1723

Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (29)

P

Padmanee Sharma

M

Michael Krainer

F

Fred Saad

Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal

D

Daniel Castellano

Hospital Universitario 12 de Octubre, Madrid

J

Jens Bedke

Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany

M

Mariusz Kwiatkowski

A

Akash Patnaik

G

Giuseppe Procopio

P

Paweł Wiechno

S

Samith Kochuparambil

C

Christian Thomas

J

José Ángel Arranz Arija

S

Steven L. McCune

S

Steinbjørn Hansen

G

Gedske Daugaard

J

Juan Ignacio Delgado Mingorance

C

Craig Kukard

S

Sumit K. Subudhi

S

Sreyashi Basu

S

Sonali Jindal

B

Bilal A. Siddiqui

A

Ana Lako

S

Saurabh Gupta

V

Viktor Fedorov

N

Neha P. Amin

A

Arancha Campos

Y

Yumeng Wang

Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences

J

Justin M. David

R

Russell K. Pachynski

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

Article Details

Journal Info

Authors (29)

Related Articles from this Journal

Synthesis of adaptive 15N-nitrosyl-Co7 nanocluster for electrocatalytic C–H functionalization

Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses

Multi-population GWAS meta-analysis identifies bladder cancer susceptibility loci and highlights genetic regulation of smoking-related risk

Genome-wide annotation of human multi-nucleotide variants reveals widespread functional differences from single nucleotide variants

Allele-specific chromatin architecture shapes imprinted domains and coordinates a distal enhancer and antisense transcription at the mouse Mest-Copg2 domain